| Business Summary | | Alkermes,
Inc.
develops
products
that
are
based
on
sophisticated
drug
delivery
technologies.
The
Company
has
several
areas
of
focus,
including
controlled,
sustained-release
of
injectable
drugs,
lasting
several
days
to
several
weeks,
utilizing
its
ProLease
and
Medisorb
technologies,
and
the
development
of
pharmaceutical
products
based
on
its
proprietary
Advanced
Inhalation
Research
(AIR)
pulmonary
technology.
The
Company's
current
focus
is
on
the
development
of
broadly
applicable
drug
delivery
technologies
that
include
injectable
sustained-release
of
proteins,
peptides
and
small
molecule
pharmaceutical
compounds,
the
pulmonary
delivery
of
both
small
molecules
and
proteins
and
peptides
and
drug
delivery
to
the
brain
across
the
blood-brain
barrier. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ALKS
develops
products
based
on
drug
delivery
technologies.
The
Co.'s
areas
of
focus
are:
controlled,
release
of
injectable
drugs,
delivery
of
drugs
into
the
brain,
oral
delivery
of
drugs
and
pulmonary
delivery
of
small
proteins.
For
the
three
months
ended
6/30/01,
revenues
fell
46%
to
$15.5
million.
Net
loss
applicable
to
Common
totalled
$8.3
million
vs.
income
of
$7.9
million.
Results
reflect
the
absence
of
milestone
revenues,
and
higher
research
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2001
Compensation | | Pay | Exer | |
| Michael Wall, 72 Chairman | -- | -- | Richard Pops, 39 CEO | $857K | $13.1M | Robert Breyer, 57 Pres,
Director | 579K | 7.7M | David Broecker, 40 COO | -- | -- | Raymond Bartus, Ph.D., 54 Sr.
VP of Preclinical R&D | -- | -- | Dollar
amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|